OMC
NKTR icon

Old Mission Capital’s Nektar Therapeutics NKTR Stock Holding History

Old Mission Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8,370
Closed -$72.2K – 1482
2023
Q2 		$72.2K Buy
+8,370
New +$89.2K ﹤0.01% 1118

Other funds holding NKTR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Old Mission Capital's NKTR Position: Q3 2023 in Review

Old Mission Capital sold out of Nektar Therapeutics (NKTR) in Q3 2023, closing a stake of 8,370 shares — an estimated $72.2K sold.

Old Mission Capital first reported a position in NKTR in Q2 2023 and held it in 1 quarter. The position peaked at $72.2K in Q2 2023. 138 funds tracked by Wall St. Rank hold NKTR as of Q3 2023.

  • Old Mission Capital reported no remaining Nektar Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Old Mission Capital sold 8,370 Nektar Therapeutics shares in Q3 2023, an estimated $72.2K.
  • Old Mission Capital first reported a position in Nektar Therapeutics in Q2 2023 and held it in 1 quarter.
  • Old Mission Capital's Nektar Therapeutics position peaked at $72.2K in Q2 2023.
  • 138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2023.

Based on Old Mission Capital's 13F filing for Q3 2023, filed 15 Nov 2023.